Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loncastuximab tesirine - ADC Therapeutics

Next Previous
Drug Profile

Loncastuximab tesirine - ADC Therapeutics

Alternative Names: ADCT-402; Anti-CD19-PBD-conjugate-ADC; Lonca-T

Latest Information Update: 14 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Cell death stimulants; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 09 Jan 2020 ADC Therapeutics intends to file BLA with the US FDA for Diffuse large B-cell lymphoma (Second-line therapy or greater) in the third quarter of 2020
  • 09 Jan 2020 ADC Therapeutics intends to launch loncastuximab tesirine for Diffuse large B-cell lymphoma (Second-line therapy or greater) in the second quarter of 2021
  • 09 Jan 2020 Efficacy and adverse events data from a phase II trial in Diffuse large B cell lymphoma (Monotherapy, Second-line therapy or greater) released by ADC Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top